GLP-1 medications, initially developed for – and approved to treat – type 2 diabetes, are now at the center of rising concerns for employers. While effective for weight loss, their high price tags are causing significant strain on pharmacy benefits budgets.
In a recent BenefitsPRO article, RxBenefits looks at how the growing use of GLP-1s – particularly for off-label purposes – is driving up costs and explores strategies employers can implement to better manage these expenses.
With prescription drug spending rising nearly 10% in 2023, the article outlines practical steps employers can take to control pharmacy costs while maintaining access to necessary medications.
